VYNE Stockholders Greenlight All Proposals for Yarrow Bioscience Reverse Merger

summarizeSummary

VYNE Therapeutics stockholders overwhelmingly approved all proposals needed to complete the reverse merger with Yarrow Bioscience, including the share issuance, reverse stock split, and authorized share increase. The vote clears the last major condition for closing the deal, which will bring a new clinical pipeline and $100 million in financing.

check_boxKey Events · M&A and Partnerships · VYNE

• All Merger Proposals Approved

  At the July 16 special meeting, stockholders approved all nine proposals, including the share issuance to Yarrow stockholders (Proposal 1: 15.9M for, 137K against), the reverse stock split (Proposal 2: 25.4M for, 551K against), and the authorized share increase to 300M (Proposal 3: 23.9M for, 2.0M against).

• Reverse Split Ratio Set

  The approved reverse stock split will be at a ratio between 1-for-10 and 1-for-70, to be determined by the board and Yarrow, aimed at meeting Nasdaq listing requirements post-merger.

• Authorized Shares Doubled

  Stockholders approved increasing authorized common shares from 150 million to 300 million, providing sufficient headroom for the merger share issuance and future equity needs.

• Yarrow Equity Plans Approved

  The Yarrow Bioscience 2026 Stock Incentive Plan and Employee Stock Purchase Plan were approved (Proposals 4 and 5), enabling the combined company to incentivize employees post-closing.

auto_awesomeAnalysis · VYNE · Life Sciences

Clearing the final stockholder hurdle, VYNE Therapeutics secured overwhelming approval for all nine proposals tied to its reverse merger with Yarrow Bioscience at the July 16 special meeting. The vote authorizes the issuance of shares representing more than 20% of VYNE's pre-merger outstanding stock, a reverse split at a ratio between 1-for-10 and 1-for-70, and an increase in authorized shares from 150 million to 300 million — each a critical step to consummate the deal. Once closed, the merger will transform VYNE into a clinical-stage biotech focused on YB-101 for Graves' disease, with the combined company set to receive $100 million in pre-closing financing. The overwhelming support (over 99% of votes cast in favor of the share issuance and reverse split) removes uncertainty and signals strong stockholder alignment behind the transaction.